-amplified Stage 2/3 Neuroblastoma: Excellent Survival in the Era of Anti-G Immunotherapy

High-risk neuroblastoma (HR-NB) includes -amplified stage 2/3, but reports covering anti-G immunotherapy, which recently became standard for HR-NB, do not provide details on this subset. We now report on all 20 -amplified stage 2/3 patients who received induction chemotherapy at our center during the era of consolidation with anti-G antibody 3F8/ granulocyte-macrophage colony-stimulating factor (GM-CSF) (2000-2015). Early in this period, consolidation included autologous stem-cell transplantation (ASCT). Event-free survival (EFS) and overall survival (OS) were estimated using Kaplan-Meier analyses. With induction, 19/20 (95%) patients achieved complete/very good partial remission (CR/VGPR) but one had progressive disease with early death. One responder did not receive consolidation and died of relapse. Five-year post-diagnosis EFS/OS rates for all 20 patients were 72%/84%. The 18 CR/VGPR patients who received consolidation had EFS/OS 81%/94% at five years from starting 3F8/GM-CSF: 4/4 ASCT patients remained relapse-free, while 11/14 non-ASCT patients remained relapse-free and two of the three relapsed patients achieved 2 CR (consolidated by retreatment with 3F8/GM-CSF) and remained in 2 CR at 36+ and 95+ months post-relapse. The 14 non-ASCT patients had EFS/OS 73.5%/93% at five years from starting 3F8/GM-CSF. This subset appears to have a good prognosis with contemporary multi-modality therapy, possibly even without ASCT.